421 related articles for article (PubMed ID: 34229721)
1. Postoperative oxaliplatin-based hyperthermic intraperitoneal chemotherapy: an effective and safe palliative treatment option for colorectal cancer with peritoneal metastasis.
Sun T; Li K; Xu G; Zhu K; Wang Q; Dang C; Yuan D
World J Surg Oncol; 2021 Jul; 19(1):200. PubMed ID: 34229721
[TBL] [Abstract][Full Text] [Related]
2. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
[No Abstract] [Full Text] [Related]
3. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351
[No Abstract] [Full Text] [Related]
4. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
[TBL] [Abstract][Full Text] [Related]
5. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W
Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
[TBL] [Abstract][Full Text] [Related]
7. High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy.
Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liu Z; Zheng Z; Chen H; Wang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X
BMC Cancer; 2021 Jan; 21(1):41. PubMed ID: 33413223
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal carcinomatosis in colorectal cancer: Defining predictive factors for successful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A pilot study.
Mahmoud AM; Ismail YM; Hussien A; Debaky Y; Ahmed IS; Mikhael HSW; Moneer M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):143-150. PubMed ID: 30472198
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
[TBL] [Abstract][Full Text] [Related]
10. In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival.
Said I; Ubink I; Ewalds RSG; Arkesteijn JGT; Verheul HMW; de Wilt JHW; Dekker HM; Bremers AJA; de Reuver PR
Ann Surg Oncol; 2022 Aug; 29(8):5256-5262. PubMed ID: 35430666
[TBL] [Abstract][Full Text] [Related]
11. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
[TBL] [Abstract][Full Text] [Related]
12. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ
Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139
[TBL] [Abstract][Full Text] [Related]
14. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study.
Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S
Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.
Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS
Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790
[TBL] [Abstract][Full Text] [Related]
16. Actual 5-Year Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis of Colorectal Origin.
Sarfaty E; Khajoueinejad N; Yu AT; Hiotis S; Golas BJ; Sarpel U; Labow DM; Cohen NA
Ann Surg Oncol; 2024 Mar; 31(3):1970-1979. PubMed ID: 37989953
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Santullo F; Vaira M; Di Lauro K; D'Acapito F; Carboni F; Giuffrè G; Donini A; Fugazzola P; Faviana P; Sorrentino L; Scapinello A; Del Bianco P; Sommariva A
Ann Surg Oncol; 2022 Jun; 29(6):3405-3417. PubMed ID: 34783946
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis.
Lin EK; Hsieh MC; Chen CH; Lu YJ; Wu SY
Medicine (Baltimore); 2016 Dec; 95(52):e5522. PubMed ID: 28033247
[TBL] [Abstract][Full Text] [Related]
19. Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study.
Solaini L; D'Acapito F; Passardi A; Framarini M; Tauceri F; Di Pietrantonio D; Frassineti GL; Casadei Gardini A; Cucchetti A; Cavaliere D; Ercolani G
World J Surg Oncol; 2019 Mar; 17(1):58. PubMed ID: 30917826
[TBL] [Abstract][Full Text] [Related]
20. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort.
Frøysnes IS; Larsen SG; Spasojevic M; Dueland S; Flatmark K
J Surg Oncol; 2016 Aug; 114(2):222-7. PubMed ID: 27173150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]